Our history

20+

20+

Years of development

1 bit

1 bit

2010

yes/no immunoassay

4 bits

4 bits

2017

4-plex yes/no immunoassay

16 bits

16 bits

2023

2-plex quanitative chemistry assays, each with 8-bits of resolution

20+

Years of development

Our history

1 bit

2010

yes/no immunoassay

4 bits

2017

4-plex yes/no immunoassay

16 bits

2023

2 plex quantitative chemistries assay with 8 plex resolution

Exponential Technology

We are leveraging microchip capabilities to dramatically miniaturize blood testing. Not only did we exceed the 8-bits of information available from a glucometer, but we observed that the amount of information we can access from a single drop of blood using digital microchips is doubling every 3 years.


The absence of a reader makes reverse compatibility a non-issue and enables rapid innovation. The passive sample preparation that relies on capillary forces improves with miniaturization.


Launching into the veterinary space is the last facet to building an exponential innovation engine for drop of blood diagnostics.

We are leveraging microchip capabilities to dramatically miniaturize blood testing. Not only did we exceed the 8-bits of information available from a glucometer, but we observed that the amount of information we can access from a single drop of blood using digital microchips is doubling every 3 years.


The absence of a reader makes reverse compatibility a non-issue and enables rapid innovation. The passive sample preparation that relies on capillary forces improves with miniaturization.


Launching into the veterinary space is the last facet to building an exponential innovation engine for drop of blood diagnostics.

Leadership Team
Octavian Florescu, CEO
Octavian Florescu, CEO

Octavian has spent more than 20 years developing microchip-based Point-of-Care devices. He received his PhD from UC Berkeley in Electrical Engineering with a minor in Molecular and Cell Biology and his BSc in Computer Engineering from University of Waterloo.

Ana Florescu, COO
Ana Florescu, COO

With a background in finance & entrepreneurship, Ana handles operations and business development at InD. Previously, she developed programs for international entrepreneurs in the Bay Area, connecting successful entrepreneurs with mentors, investors, and corporate partners.


Advisory Team

Clint Severson

Clint Severson was CEO of Abaxis from 1995 until its sale in 2018 for $2B to Zoetis. He grew the company from $6M in sales to over $300M.

Austin Viall, DVM

Associate Professor, Pathology, Microbiology & Immunology at UC Davis.

W. Frank Peacock IV, MD, FACEP, FACC

Professor of Emergency Medicine and Vice Chair for Research in the department of Emergency Medicine at Baylor College of Medicine, in Houston, Texas.

Erica Behling-Kelly, DVM, PhD, DACVP

Chief Medical Officer,Ellie Diagnostics. Former Director of the Clinical Pathology Laboratory at Cornell University.